What is it about?
We found that the IL7 receptor and CXCR4 form a signalling platform that brings BCR-ABL1 and JAK kinases together in Philadelphia-positive acute lymphoblastic leukaemia. IL7 supported survival during kinase-inhibitor treatment, while an anti-IL7R antibody prevented leukaemia development in patient-derived models, including drug-resistant disease.
Featured Image
Photo by Cassi Josh on Unsplash
Why is it important?
Resistance to BCR-ABL1 inhibitors limits treatment for some patients. Targeting the IL7R-CXCR4 signalling platform offers a possible alternative strategy and provides a biological explanation for how leukaemia cells can survive standard kinase inhibition.
Perspectives
From my perspective, this work matters because Resistance to BCR-ABL1 inhibitors limits treatment for some patients. I hope the findings support further research and informed, evidence-based decisions.
Yasar Yousafzai
Khyber Medical University
Read the Original
This page is a summary of: Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia, Nature Communications, June 2020, Springer Science + Business Media,
DOI: 10.1038/s41467-020-16927-w.
You can read the full text:
Contributors
The following have contributed to this page
